Laurence Zitvogel

From Wikipedia, the free encyclopedia

Laurence Zitvogel
Born (1963-12-25) 25 December 1963 (age 60)
Sureness, France
NationalityFrench
Alma materParis University
Occupation(s)Oncologist, immunologist, researcher
HonoursBaillet Latour Awarded by the Belgian Monarchy

Laurence Zitvogel is a French physician-scientist specializing in oncology and immunology. Zitvogel is a French physician clinical oncologist, researcher in the Laboratory of Tumor Immunology and Immunotherapy and a Professor at Université Paris-Saclay.[1] Zitvogel was born on December 25, 1963, attended medical school in 1992, but Zitvogel kickstarted her scientific career started at the University of Pittsburgh when she took part in Michael Lotze’s laboratory.[2] Zitvogel has spent 30 year studying the correlation between the immune system and the success of cancer treatments.[3] Since then, Zitvogel has received various honors and awards ranging from the Bob Pinedo Cancer Care Award 2022 to the ESMO Award for Immuno-Oncology for her advancements within the field. Her primary research experience is in exosomes[4] and the biological impact of structural abnormalities on malignant neoplasms[5] and anti-tumor therapy.[6] Through her work as a professor and a researcher, Zitvogel found that mouse models, revealed that chemotherapy could retard the growth of tumors.[7] Her team reported the first anticancer probiotic, Enterococcus hirae,[8] and Zitvogel is currently finding an effective and inexpensive diagnostic test to predict dysbiosis and to quickly correct it.[1] Zitvogel is currently pursuing the promising lead on the role of certain gut microbiotes in anti-tumour immunotherapy.[1]

Personal life[edit]

Laurence Zitvogel was born in Suresnes, France on 25 December 1963.[9] Zitvogel has worked with her spouse, Guido Kroemer,[10] since 2001.[11]

Education[edit]

Zitvogel earned her degree in Medical Oncology from the University of Paris in 1992, and received her Ph.D in Immunology at the University of Pittsburgh Cancer Institute and the Gustav Roussy Cancer Center in 1995.[12] Zitvogel started her scientific career at the University of Pittsburgh (USA) in 1993.[13]

Career and Leadership[edit]

Zitvogel supervised the work that analyzed the multifaceted modes of action of this anticancer probiotic.[8] Zitvogel leads the French RHU Torino-Lumière and European Oncobiome consortia for the development of tests for gut dysbiosis associated with frequent cancers.[1] Zitvogel has authored or co-authored over 350 publications.[14] Zitvogel is also the Editor-in-Chief and founder of one of the first journals in immune-oncology, OncoImmunology.[15] Zitvogel is Professor of Immunobiology at the University of Paris XI Medical School and scientific director at the Department of Immuno-Oncology, Gustave Roussy Cancer Center, in Villejuif, France.[16] Zitovgel is also the director of U1015 INSERM Tumour Immunology and Immunotherapy Laboratory at INSERM and co-director of the Center for Clinical Investigation in Biotherapies of Cancer, INSERM.[15] Zitvogel is also the company co-founder of EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products as adjuncts to cancer immunotherapy.[17] Zitvogel has led a team that found that bacteria in the gut had a major effect on the efficacy of checkpoint inhibitors in mice.[18]

Research[edit]

Zitvogel became Director of Research for the University of Paris XI in 1998.[19] Her work focuses on intestinal bacterial flora.[20][21][22] Her primary research objectives are to identify cell adhesion molecules that serve as actionable checkpoints for tumor surveillance.[5] Zitvogel directs a research group on tumor immunology and immunotherapy of cancer at the Institut Gustave Roussy[23] where her team has been focused on discovery and validation for antibody combination therapies. [24]

Zitvogel found that cancer therapies with long-term beneficial effects may have limited impact on local disease but should activate a relevant adaptive immune reaction.[25] Pioneering work by Laurence Zitvogel and Guido Kroemer, in mouse models, revealed that chemotherapy could retard the growth of tumors growing on immunocompetent but had no effect on tumors established on immunodeficient mice.[25] In 2013, Zitvogel's work was the first to report the first anticancer probiotic, Enterococcus hirae isolated from spleens of animals treated with the immunological adjuvant cyclophosphamide.[26] Zitvogel and her team of 30 people are at the origin of a major discovery in the treatment of cancers, which today gives this researcher a new scientific identity.[1]  Zitvogel set up a patient diagnosis platform, this platform allows the patient's tumor to be removed when the operation is performed.[1] Zitvogel hypothesized that disruption of the MAdCAM-1–α4β7 interaction that retains Treg17 cells might cause their migration from the gut to tumors and thereby compromise the anticancer effects of ICIs.[27] Accompanying this, Zitvogel saw that the relocation of enterotropic and immunosuppressive Treg17 cells to cancerous tissue (tumors and tdLNs) is repressed by the molecular interaction between the HEV addressin MAdCAM-1 and the integrin α4β7 expressed by Treg17 cells.[27]  Zitvogel's research also revealed that antibiotics administered before or during treatment may worsen the efficacy of immunotherapy. [28] Zitvogel examined the connections between nutrition, inflammation, and the immune systems impact on cancer.[29] Correspondibly, Zitvogel found that nutritional interventions are emerging as novel strategies for improving the outcome of treatments with PD-1/PD-L1–targeting ICIs.[30] Continuing on with Zitvogel's cancer research, Zitvogel found that probiotics used as complement to the existing therapeutic arsenal (surgery, radiotherapy, chemotherapy, hormone therapy, immunotherapy) could become a sixth therapeutic modality against cancer.[31] Zitovgel's ongoing research falls into three main categories: studying the modes of action of immune checkpoint inhibitors and seeking predictors of response to immunomodulators; defining the role of the gut microbiome in cancer immunosurveil.[15]

Awards[edit]

Zitvogel received the INSERM prize for research in clinical and therapeutic approaches to cancer in 2007.[32] Zitvogel received the first European Society for Medical Oncology (ESMO) award during her lecture titled Introducing the gut microbiome into the complexity of anticancer immunosurveillance in 2017.[33] Zitvogel also received the ASCO-SITC, the Brupbacher Award in 2017, the Charles Rodolphe Brupbacher Prize for Cancer Research in 2017[34], and the ESMO Immuno-Oncology Award in 2017.[15]

Zitvogel obtained the Baillet Latour Prize from Belgium in 2018 with her co-researcher Kroemer for their research on mechanisms of cancer immune surveillance,[35] and the Jakob-Herz Prize in 2018.[36]

Zitvogel won the ARC Griffuel Prize in 2019[37],

In 2022, Zitvogel was awarded with the Bob Pinedo Cancer Care Award.[28] The Bob Pinedo Cancer Care Award is a biennial award given to researchers and research teams who provide outstanding contribution to cancer research and patient care.[28] Zitvogel received this award for discovering how gut microbiomes influence anticancer therapy and pioneering research on this topic.[28]

References[edit]

  1. ^ a b c d e f "Laurence Zitvogel: Gut bacteria that cure cancer". Université Paris-Saclay. 11 February 2020. Retrieved 31 May 2024.
  2. ^ Moreira, Sarah. "Laurence Zitvogel". The Barcelona Debates on the Human Microbiome 2024. Retrieved 31 May 2024.
  3. ^ Jalinière, Hugo (20 March 2016). "Laurence Zitvogel : l'ennemie intime du cancer". Sciences et Avenir (in French). Retrieved 31 May 2024.
  4. ^ Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. (1998-05). "Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes". Nature Medicine. 4 (5): 594–600. doi:10.1038/nm0598-594. ISSN 1078-8956. PMID 9585234. {{cite journal}}: Check date values in: |date= (help)
  5. ^ a b Zitvogel, Laurence; Tesniere, Antoine; Kroemer, Guido (2006-10). "Cancer despite immunosurveillance: immunoselection and immunosubversion". Nature Reviews. Immunology. 6 (10): 715–727. doi:10.1038/nri1936. ISSN 1474-1733. PMID 16977338. {{cite journal}}: Check date values in: |date= (help)
  6. ^ Vétizou, Marie; Daillère, Romain; Zitvogel, Laurence (2016-11). "[The role of intestinal microbiota in the response to anti-tumor therapies]". Medecine Sciences: M/S. 32 (11): 974–982. doi:10.1051/medsci/20163211013. ISSN 1958-5381. PMID 28008838. {{cite journal}}: Check date values in: |date= (help)
  7. ^ Fridman, Wolf H.; Teillaud, Jean-Luc; Sautès-Fridman, Catherine; Pagès, Franck; Galon, Jérôme; Zucman-Rossi, Jessica; Tartour, Eric; Zitvogel, Laurence; Kroemer, Guido (1 December 2011). "The Ultimate Goal of Curative Anti-Cancer Therapies: Inducing an Adaptive Anti-Tumor Immune Response". Frontiers in Immunology. 2: 66. doi:10.3389/fimmu.2011.00066. ISSN 1664-3224. PMC 3341952. PMID 22566855.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ^ a b Goubet, Anne-Gaëlle; Wheeler, Richard; Fluckiger, Aurélie; Qu, Bo; Lemaître, Fabien; Iribarren, Kristina; Mondragón, Laura; Tidjani Alou, Maryam; Pizzato, Eugénie; Durand, Sylvère; Derosa, Lisa; Aprahamian, Fanny; Bossut, Noélie; Moya-Nilges, Maryse; Derrien, Diane (2021-07). "Multifaceted modes of action of the anticancer probiotic Enterococcus hirae". Cell Death and Differentiation. 28 (7): 2276–2295. doi:10.1038/s41418-021-00753-8. ISSN 1350-9047. PMC 8257780. PMID 33976389. {{cite journal}}: Check date values in: |date= (help)
  9. ^ Jalinière, Hugo (20 March 2016). "Laurence Zitvogel : l'ennemie intime du cancer" [Laurence Zitvogel. The intimate enemy of cancer]. Science et Avenir (in French). Retrieved 26 June 2020.
  10. ^ Kroemer, Guido (2017). "Cancer cell stress and death – cell-autonomous and immunological considerations" (PDF). Charles Rodolphe Brupbacher Foundation. Retrieved 26 June 2020.
  11. ^ Barret, Anna-Laure (21 June 2017). "L'amour contre le cancer" [Love against cancer]. Le Journal de Dimanche (in French). Retrieved 26 June 2020.
  12. ^ "Zitvogel Laurence". www.ae-info.org. The Academy of Europe. Retrieved 23 June 2020.
  13. ^ "Laurence Zitvogel, MD, PhD - Gustave Roussy Cancer Centre | Antibody Engineering & Therapeutics Series Speaker". informaconnect.com. Retrieved 31 May 2024.
  14. ^ "Shop Talk". Oncology Times. 39 (22): 69. 25 November 2017. doi:10.1097/01.COT.0000527395.64210.f0. ISSN 0276-2234.
  15. ^ a b c d ESMO. "First ESMO Award in Immuno-Oncology Goes to Laurence Zitvogel". www.esmo.org. Retrieved 31 May 2024.
  16. ^ November 10, The ASCO Post Staff; 2017. "First ESMO Award for Immuno-Oncology Presented to Laurence Zitvogel, MD, PhD". ascopost.com. Retrieved 31 May 2024. {{cite web}}: |last2= has numeric name (help)CS1 maint: numeric names: authors list (link)
  17. ^ "EverImmune appoints Prof. Laurence Zitvogel as president of scientific advisory board | Andrew Lloyd & Associates". ala.associates. Retrieved 31 May 2024. {{cite web}}: no-break space character in |title= at position 44 (help)
  18. ^ Owens, Brian (1 February 2018). "Gut bacteria link to immunotherapy sparks interest". Nature Biotechnology. 36 (2): 121–122. doi:10.1038/nbt0218-121. ISSN 1546-1696.
  19. ^ "Enterophages, new sources in immunology" (PDF). Comprehensive Academy for Advanced Oncology. Retrieved 26 June 2020.
  20. ^ Yonekura, Satoru (11 January 2017). "theses.fr". thesses.fr.
  21. ^ Zitvogel, Laurence (11 February 2020). "Des bacteries intestinales qui soignent les cancer". Universite de Paris-Sarclay.
  22. ^ "Laurence Zitvogel : Des bactéries intestinales qui soignent les cancers". Université Paris-Saclay (in French). 11 February 2020. Retrieved 23 June 2020.
  23. ^ "Professeur Laurence Zitvogel" [Professor Laurence Zitvogel]. Gustave Roussy Cancer Campus (in French). Retrieved 26 June 2020.
  24. ^ Zitvogel, Laurence; Kroemer, Guido (1 November 2012). "Targeting PD-1/PD-L1 interactions for cancer immunotherapy". Oncoimmunology. 1 (8): 1223–1225. doi:10.4161/onci.21335. ISSN 2162-4011. PMC 3518493. PMID 23243584.
  25. ^ a b Fridman, Wolf H.; Teillaud, Jean-Luc; Sautès-Fridman, Catherine; Pagès, Franck; Galon, Jérôme; Zucman-Rossi, Jessica; Tartour, Eric; Zitvogel, Laurence; Kroemer, Guido (1 December 2011). "The Ultimate Goal of Curative Anti-Cancer Therapies: Inducing an Adaptive Anti-Tumor Immune Response". Frontiers in Immunology. 2: 66. doi:10.3389/fimmu.2011.00066. ISSN 1664-3224. PMC 3341952. PMID 22566855.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  26. ^ Goubet, Anne-Gaëlle; Wheeler, Richard; Fluckiger, Aurélie; Qu, Bo; Lemaître, Fabien; Iribarren, Kristina; Mondragón, Laura; Tidjani Alou, Maryam; Pizzato, Eugénie; Durand, Sylvère; Derosa, Lisa; Aprahamian, Fanny; Bossut, Noélie; Moya-Nilges, Maryse; Derrien, Diane (2021-07). "Multifaceted modes of action of the anticancer probiotic Enterococcus hirae". Cell Death and Differentiation. 28 (7): 2276–2295. doi:10.1038/s41418-021-00753-8. ISSN 1350-9047. PMC 8257780. PMID 33976389. {{cite journal}}: Check date values in: |date= (help)
  27. ^ a b Fidelle, Marine; Rauber, Conrad; Alves Costa Silva, Carolina; Tian, Ai-Ling; Lahmar, Imran; de La Varende, Anne-Laure Mallard; Zhao, Liwei; Thelemaque, Cassandra; Lebhar, Isabelle; Messaoudene, Meriem; Pizzato, Eugenie; Birebent, Roxanne; Mbogning Fonkou, Maxime Descartes; Zoppi, Silvia; Reni, Anna (9 June 2023). "A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers". Science. 380 (6649). doi:10.1126/science.abo2296. ISSN 0036-8075.
  28. ^ a b c d "Bob Pinedo Cancer Care Award 2022 for Laurence Zitvogel - KNAW". knaw.nl (in Dutch). Retrieved 9 May 2024.
  29. ^ Zitvogel, Laurence; Pietrocola, Federico; Kroemer, Guido (2017-08). "Nutrition, inflammation and cancer". Nature Immunology. 18 (8): 843–850. doi:10.1038/ni.3754. ISSN 1529-2916. {{cite journal}}: Check date values in: |date= (help)
  30. ^ Zitvogel, Laurence; Kroemer, Guido (1 June 2022). "Boosting the immunotherapy response by nutritional interventions". The Journal of Clinical Investigation. 132 (11). doi:10.1172/JCI161483. ISSN 0021-9738.
  31. ^ "Expert interview : Pr. Laurence Zitvogel". Biocodex Microbiota Institute. Retrieved 31 May 2024.
  32. ^ "Laurence Zitvogel, Prix Recherche Clinique et thérapeutique 2007" [Laurence Zitvogel, 2007 Clinical and Therapeutic Research Prize]. INSERM. Retrieved 26 June 2020.
  33. ^ "First ESMO award for Immunology Oncology goes to Laurence Zitvogel". eurakalert.org (Press release). European Society for Medical Oncology. 19 October 2017. Retrieved 26 June 2020.
  34. ^ "Brupbacher Prize – Charles Rodolphe Brupbacher Foundation". Charles Rodolphe Brupbacher Stiftung. Retrieved 31 May 2024.
  35. ^ "Les professeurs Laurence Zitvogel et Guido Kroemer reçoivent le Prix Baillet Latour de la Santé 2018 pour leurs découvertes fondamentales dans le domaine du cancer" [Professors Laurence Zitvogel and Guido Kroemer receive the 2018 Baillet Latour Award For Health for their basic discoveries in the cancer field] (PDF) (in French). Fonds Baillet Latour. April 2018. Retrieved 26 June 2020.
  36. ^ "Jakob-Herz Prize 2018". Faculty of Medicine. 5 February 2018. Retrieved 31 May 2024.
  37. ^ "Steve Jackson to receive ARC Foundation Léopold Griffuel Award | CRUK CC". crukcambridgecentre.org.uk. Retrieved 31 May 2024.

Jalinière, Hugo (20 March 2016). "Laurence Zitvogel : l'ennemie intime du cancer" [Laurence Zitvogel. The intimate enemy of cancer]. Science et Avenir (in French). Retrieved 26 June 2020.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Laurence_Zitvogel&oldid=1226544489"